Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Dec 1;214(11):1717-1727.
doi: 10.1093/infdis/jiw414. Epub 2016 Sep 7.

Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults

Anuradha Madan  1 , Nathan Segall  2 , Murdo Ferguson  3 , Louise Frenette  4 , Robin Kroll  5 , Damien Friel  6 , Jyoti Soni  7 , Ping Li  8 , Bruce L Innis  8 , Anne Schuind  8
Affiliations
Clinical Trial

Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults

Anuradha Madan et al. J Infect Dis. .

Abstract

Background: Almost 700 cases of human infection with avian influenza A/H7N9 have been reported since 2013. Pandemic preparedness strategies include H7N9 vaccine development.

Methods: We evaluated an inactivated H7N9 vaccine in an observer-blind study in healthy adults aged 18-64 years. Participants (420) were randomized to receive 1 of 4 AS03-adjuvanted vaccines (low or medium dose of hemagglutinin with AS03A or AS03B), one nonadjuvanted vaccine, or placebo. The coprimary immunogenicity objective determined whether adjuvanted vaccines elicited an immune response against the vaccine-homologous virus, 21 days after the second vaccine dose per US and European licensure criteria in the per-protocol cohort (n = 389).

Results: All adjuvanted vaccines met regulatory acceptance criteria. In groups receiving adjuvanted formulations, seroconversion rates were ≥85.7%, seroprotection rates ≥91.1%, and geometric mean titers ≥92.9% versus 23.2%, 28.6%, and 17.2 for the nonadjuvanted vaccine. The AS03 adjuvant enhanced immune response at antigen-sparing doses. Injection site pain occurred more frequently with adjuvanted vaccines (in ≤98.3% of vaccinees) than with the nonadjuvanted vaccine (40.7%) or placebo (20.0%). None of the 20 serious adverse events reported were related to vaccination.

Conclusions: Two doses of AS03-adjuvanted H7N9 vaccine were well tolerated and induced a robust antibody response at antigen-sparing doses in healthy adults.

Clinical trials registration: NCT01999842.

Keywords: AS03; H7N9; adjuvant system; antigen sparing; influenza; pandemic; vaccine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Participant flow chart. Values represent numbers of participants. Abbreviations: HA/AS03A, hemagglutinin (HA) adjuvanted with AS03A; HA/AS03B, hemagglutinin (HA) adjuvanted with AS03B.
Figure 2.
Figure 2.
Seropositivity rate and geometric mean titer (GMT) for vaccine-homologous (A) and vaccine-heterologous (B) microneutralization antibodies (adapted per-protocol cohort). The vaccine homologous strain used for testing was a H7N9 virus developed by reverse genetics with hemagglutinin (HA) and neuraminidase genes derived from A/Anhui/1/2013 (H7N9) and 6 genes from A/PR/8/34. The vaccine heterologous strain was a H7N1 virus developed by reverse genetics with the HA gene derived from A/mallard/Netherlands/12/2000 (H7N3) and 7 genes from A/PR/8/34. Bars represent GMT values; error bars, 95% confidence intervals (CI); percentages above the bars, seropositivity rate; and horizontal gridline, cutoff value for the assay. The adapted per-protocol cohort includes data for days 0, 21, and 42 from the day 42 per-protocol cohort; day 182 data from the day 182 per-protocol cohort; and day 385 data from the day 385 per-protocol cohort. Day 21 was 21 days after the first vaccination, day 42 was 21 days after the second vaccination, and day 182 was 182 days after the first vaccination. Abbreviations: d, day; HD, high-dose; LD, low-dose; MD, medium-dose; Pre, prevaccination measurement.
See this image and copyright information in PMC

References

    1. Koopmans M, Wilbrink B, Conyn M et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004; 363:587–93. - PubMed
    1. World Health Organization. WHO risk assessment of human infections with avian influenza A(H7N9) virus. 23 February 2015 who.int/influenza/human_animal_interface/influenza_h7n9/Risk_Assessment/en Accessed 2 April 2015.
    1. World Health Organization. Influenza at the human-animal interface: summary and assessment as of 14 December 2015 http://www.who.int/influenza/human_animal_interface/Influenza_Summary_IR... Accessed 10 January 2016.
    1. To KK, Chan JF, Yuen KY. Viral lung infections: epidemiology, virology, clinical features, and management of avian influenza A(H7N9). Curr Opin Pulm Med 2014; 20:225–32. - PubMed
    1. Jonges M, Welkers MR, Jeeninga RE et al. Emergence of the virulence-associated PB2 E627K substitution in a fatal human case of highly pathogenic avian influenza virus A(H7N7) infection as determined by Illumina ultra-deep sequencing. J Virol 2014; 88:1694–702. - PMC - PubMed

Publication types

MeSH terms

Associated data